What break? Sarepta vet Ed Kaye quickly pivots to the helm of another biotech upstart with a $40M bankroll
After Ed Kaye left the helm at Sarepta last August, he promised his wife he’d take some time off before starting his next job in biotech.
Then the calls started coming in.
“The phone rang off the hook,” says Kaye, a popular figure in the bustling Cambridge/Boston hub who has a resume that covers every aspect of biotech existence. It’s the kind of background that venture groups love.
“Within weeks I had 6 offers,” he says without even a slight trace of boasting. One fund he talked with “said that if we had 20 people like you, we’d start 20 companies.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.